Patent intelligence · US
US 10973817
Pharmaceutical compounds
Pharmaceutical compounds
Patent details — US 10973817
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 13, 2021
- Expiration
- Apr 8, 2041
- Applicant
- SENTINEL ONCOLOGY LIMITED
- Claims
- 25
- CPC classes
- A61K, A61K31/4155, A61K31/454, A61K31/497
Quick answer
US 10973817 (Pharmaceutical compounds) is held by SENTINEL ONCOLOGY LIMITED. Status: granted. Granted Apr 13, 2021. Expires Apr 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SENTINEL ONCOLOGY LIMITED
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/4155, A61K31/454, A61K31/497, A61K31/5377, A61K31/551
More from SENTINEL ONCOLOGY LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10973817?
US 10973817 (Pharmaceutical compounds) is held by SENTINEL ONCOLOGY LIMITED. Status: granted. Granted Apr 13, 2021. Expires Apr 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10973817?
SENTINEL ONCOLOGY LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10973817 expire?
Our index shows an expiration date of Apr 8, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.